{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T19:41:59Z","timestamp":1789760519431,"version":"4.0.1"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-025-11319-1","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T14:43:03Z","timestamp":1752590583000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Experience of research nurses with oral encochleated amphotericin B for treatment of cryptococcal meningitis in a resource-limited setting"],"prefix":"10.1186","volume":"25","author":[{"given":"Cynthia","family":"Ahimbisibwe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Kwizera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane Frances","family":"Ndyetukira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivie Carolyne","family":"Namujju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alisat","family":"Sadiq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mucunguzi","family":"Atukunda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caleb P.","family":"Skipper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Boulware","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B.","family":"Meya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,15]]},"reference":[{"issue":"3","key":"11319_CR1","doi-asserted-by":"publisher","first-page":"e101","DOI":"10.1097\/QAI.0b013e31828e1e56","volume":"63","author":"KN Durski","year":"2013","unstructured":"Durski KN, Kuntz KM, Yasukawa K, Virnig BA, Meya DB, Boulware DR. Cost-effective diagnostic checklists for meningitis in resource-limited settings. J Acquir Immune Defic Syndr. 2013;63(3):e101\u2013108.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"Suppl 5","key":"11319_CR2","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/myc.12387","volume":"58","author":"R Parkes-Ratanshi","year":"2015","unstructured":"Parkes-Ratanshi R, Achan B, Kwizera R, Kambugu A, Meya D, Denning DW. Cryptococcal disease and the burden of other fungal diseases in Uganda; where are the knowledge gaps and how can we fill them? Mycoses. 2015;58(Suppl 5):85\u201393.","journal-title":"Mycoses"},{"issue":"8","key":"11319_CR3","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/S1473-3099(17)30243-8","volume":"17","author":"R Rajasingham","year":"2017","unstructured":"Rajasingham R, Smith RM, Park BJ, Jarvis JN, Govender NP, Chiller TM, Denning DW, Loyse A, Boulware DR. Global burden of disease of HIV-associated Cryptococcal meningitis: an updated analysis. Lancet Infect Dis. 2017;17(8):873\u201381.","journal-title":"Lancet Infect Dis"},{"issue":"12","key":"11319_CR4","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1016\/S1473-3099(22)00499-6","volume":"22","author":"R Rajasingham","year":"2022","unstructured":"Rajasingham R, Govender NP, Jordan A, Loyse A, Shroufi A, Denning DW, Meya DB, Chiller TM, Boulware DR. The global burden of HIV-associated Cryptococcal infection in adults in 2020: a modelling analysis. Lancet Infect Dis. 2022;22(12):1748\u201355.","journal-title":"Lancet Infect Dis"},{"key":"11319_CR5","unstructured":"Guidelines for diagnosing. preventing and managing cryptococcal disease among adults, adolescents and children living with HIV. https:\/\/www.who.int\/publications\/i\/item\/9789240052178."},{"issue":"2","key":"11319_CR6","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1007\/s40475-015-0046-y","volume":"2","author":"M Abassi","year":"2015","unstructured":"Abassi M, Boulware DR, Rhein J. Cryptococcal meningitis: diagnosis and management update. Curr Trop Med Rep. 2015;2(2):90\u20139.","journal-title":"Curr Trop Med Rep"},{"issue":"9","key":"11319_CR7","doi-asserted-by":"publisher","first-page":"e1001316","DOI":"10.1371\/journal.pmed.1001316","volume":"9","author":"R Rajasingham","year":"2012","unstructured":"Rajasingham R, Rolfes MA, Birkenkamp KE, Meya DB, Boulware DR. Cryptococcal meningitis treatment strategies in resource-limited settings: a cost-effectiveness analysis. PLoS Med. 2012;9(9):e1001316.","journal-title":"PLoS Med"},{"key":"11319_CR8","doi-asserted-by":"crossref","unstructured":"Ndyetukira JF, Kwizera R, Kugonza F, Ahimbisibwe C, Namujju C, Sadiq A, Namudde A, Williams D, Abassi M, Rhein J, et al. The conundrum of clinical trials and standard of care in sub-Saharan Africa\u2013 the research nurse perspective. J Res Nurs. 2019;24(8):649-60.","DOI":"10.1177\/1744987118824625"},{"issue":"12","key":"11319_CR9","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1056\/NEJMoa2111904","volume":"386","author":"JN Jarvis","year":"2022","unstructured":"Jarvis JN, Lawrence DS, Meya DB, Kagimu E, Kasibante J, Mpoza E, Rutakingirwa MK, Ssebambulidde K, Tugume L, Rhein J, et al. Single-Dose liposomal amphotericin B treatment for Cryptococcal meningitis. N Engl J Med. 2022;386(12):1109\u201320.","journal-title":"N Engl J Med"},{"issue":"2","key":"11319_CR10","doi-asserted-by":"publisher","first-page":"66","DOI":"10.3390\/jof6020066","volume":"6","author":"M Aigner","year":"2020","unstructured":"Aigner M, Lass-Fl\u00f6rl C. Encochleated amphotericin B: is the oral availability of amphotericin B finally reached? J Fungi. 2020;6(2):66.","journal-title":"J Fungi"},{"issue":"12","key":"11319_CR11","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1093\/cid\/ciad440","volume":"77","author":"DR Boulware","year":"2023","unstructured":"Boulware DR, Atukunda M, Kagimu E, Musubire AK, Akampurira A, Tugume L, Ssebambulidde K, Kasibante J, Nsangi L, Mugabi T, et al. Oral lipid nanocrystal amphotericin B for Cryptococcal meningitis: A randomized clinical trial. Clin Infect Diseases: Official Publication Infect Dis Soc Am. 2023;77(12):1659\u201367.","journal-title":"Clin Infect Diseases: Official Publication Infect Dis Soc Am"},{"issue":"10","key":"11319_CR12","doi-asserted-by":"publisher","first-page":"e00838","DOI":"10.1128\/AAC.00838-20","volume":"64","author":"CP Skipper","year":"2020","unstructured":"Skipper CP, Atukunda M, Stadelman A, Engen NW, Bangdiwala AS, Hullsiek KH, Abassi M, Rhein J, Nicol MR, Laker E, et al. Phase I enact trial of the safety and tolerability of a novel oral formulation of amphotericin B. Antimicrob Agents Chemother. 2020;64(10):e00838\u201300820.","journal-title":"Antimicrob Agents Chemother"},{"key":"11319_CR13","doi-asserted-by":"publisher","unstructured":"Stott KE, Beardsley J, Whalley S, Kibengo FM, Mai NTH, T\u00f9ng NLN, Cuc NTK, Kolamunnage-Dona R, Hope W, Day J. Population pharmacokinetic model and meta-analysis of outcomes of amphotericin b deoxycholate use in adults with cryptococcal meningitis. Antimicrob Agents Chemother. 2018;62(7):e02526-02517. https:\/\/doi.org\/10.1128\/AAC.02526-17.","DOI":"10.1128\/AAC.02526-17"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11319-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-025-11319-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11319-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T10:58:16Z","timestamp":1757242696000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-025-11319-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,15]]},"references-count":13,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["11319"],"URL":"https:\/\/doi.org\/10.1186\/s12879-025-11319-1","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,15]]},"assertion":[{"value":"23 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This was an observational sub-study that was nested under the ENACT trial which was approved by the Mulago Hospital Research Ethics Committee (1195); University of Minnesota Ethics Committee (STUDY00000139); Uganda National Council of Science & Technology (HS 2351); Uganda National Drug Authority (854\/NDA\/DPS\/08\/2018); United States Food and Drug Administration (IND 72807). All participants were adults aged 18 years and above. Participants provided informed consent for study participation in the ENACT trial and all its sub-studies including storage of samples for future use. The study was carried out in compliance with the international good clinical practice guidelines and the Helsinki Declaration.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"920"}}